Globus Medical, Inc.

Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026

Globus Medical will showcase its new SCRIPT patient-specific spinal implant platform and the XLIF Prone Procedural Solution at the NASS annual meeting in San Antonio, October 14-17. SCRIPT is FDA-cleared and marks the company's entry into patient-specific spine implants, with plans exportable into its ExcelsiusGPS and ExcelsiusHub robotic navigation ecosystem ahead of commercialization. The XLIF Prone solution bundles a patient positioner and MaXcess Air retractor to create a connected prone lateral workflow, reinforcing the company's integrated spine portfolio strategy.

•11d ago

Globus Medical Announces CE Mark for Excelsius3D™ Imaging System

Globus Medical received CE mark approval for its Excelsius3D™ intelligent 3-in-1 imaging system, clearing the device for commercial sale in the European Union and the United Kingdom. Excelsius3D™ combines 3D cone-beam CT, 2D fluoroscopy, and digital radiography in a single mobile intraoperative platform that integrates with the ExcelsiusGPS™ robotic navigation system, deepening the company's Excelsius™ Ecosystem internationally. The system was FDA 510(k)-cleared in 2021; with CE marking now in hand, Globus will begin commercializing Excelsius3D™ across EU and UK markets, adding an international growth avenue for its imaging and robotics franchise.

•1mo ago

Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions

Globus Medical acquired Higgs Boson Health, a digital healthcare company incubated at Duke University, to bolster its AI-driven surgical intelligence capabilities. The acquisition is intended to integrate digital solutions across the full patient journey, aiming to improve long-term musculoskeletal surgery outcomes. Leadership stated that Higgs Boson's team of software developers and AI scientists will join Globus to advance its ecosystem strategy.

•1mo ago

GMED: 10-Q · periodic report

Globus Medical's Q2 2026 net sales rose 5.9% year over year to $789.6 million with diluted EPS of $1.10. Operating income more than doubled to $182.4 million from $76.1 million as the company lapped prior-year Nevro merger costs, restructuring charges and a $110.6 million one-time bargain purchase gain that inflated the year-ago net income comparison. First-half 2026 net sales grew 15.3% to $1.55 billion, aided by the April 2025 Nevro acquisition, and operating cash flow jumped to $412.1 million from $255.2 million. International sales rose 18.0% in the quarter while U.S. sales grew 3.0%. The balance sheet is essentially debt-free: the company held $507.7 million in cash with no borrowings under its $400 million revolver after repaying $450 million of convertible notes in March 2025. Management repurchased 1.6 million shares for $136.1 million at an average of $82.96 in Q2, leaving $253.9 million remaining under the $500 million authorization. Watch items include Nevro U.S. sales declining $15.1 million in the quarter, U.S. Enabling Technologies (robotics) sales down $12.3 million on lower unit placements, and ongoing litigation including a $43.1 million accrual for the Pimenta verdict against NuVasive, which is under appeal.

SEC 10-Q•2mo ago

Globus Medical Reports Second Quarter 2026 Results

Globus Medical reported Q2 revenue of $789.6 million, up 5.9% year-over-year, with base business growth accelerating to 9% excluding the Nevro acquisition. Non-GAAP EPS surged 55.8% to $1.34, driven by 200 basis points of adjusted gross margin expansion and record non-GAAP net income. The company raised its full-year 2026 Non-GAAP EPS guidance to $4.95-$5.05, up from a prior range of $4.70-$4.80, while reaffirming its revenue outlook of $3.18 billion to $3.22 billion.

•2mo ago

Globus Medical Reports First Quarter 2026 Results

Globus Medical reported Q1 2026 revenue of $759.9 million, up 27% year-over-year, driven by 13.2% organic base business growth and the acquisition of Nevro. GAAP diluted EPS increased 66.6% to $0.90, while Non-GAAP EPS rose 64.7% to $1.12, fueled by margin expansion and operating leverage. The company reaffirmed its full-year revenue guidance of $3.18B-$3.22B and raised its Non-GAAP EPS outlook to $4.70-$4.80, up from the prior range of $4.40-$4.50.

•5mo ago